PT2659881T - Formulação de fármaco de libertação retardada - Google Patents

Formulação de fármaco de libertação retardada Download PDF

Info

Publication number
PT2659881T
PT2659881T PT121661102T PT12166110T PT2659881T PT 2659881 T PT2659881 T PT 2659881T PT 121661102 T PT121661102 T PT 121661102T PT 12166110 T PT12166110 T PT 12166110T PT 2659881 T PT2659881 T PT 2659881T
Authority
PT
Portugal
Prior art keywords
polymeric material
coating
polymer
core
release drug
Prior art date
Application number
PT121661102T
Other languages
English (en)
Portuguese (pt)
Inventor
Buser Thomas
Carlos Bravo Gonzales Roberto
Jean Claude Goutte Frederic
Waseh Basit Abdul
Jose Oliveira Varum Felipe
Cristina Freire Ana
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2659881(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of PT2659881T publication Critical patent/PT2659881T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Laminated Bodies (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Grain Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT121661102T 2012-04-30 2012-04-30 Formulação de fármaco de libertação retardada PT2659881T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12166110.2A EP2659881B1 (en) 2012-04-30 2012-04-30 A delayed release drug formulation

Publications (1)

Publication Number Publication Date
PT2659881T true PT2659881T (pt) 2018-01-29

Family

ID=46025554

Family Applications (5)

Application Number Title Priority Date Filing Date
PT121661102T PT2659881T (pt) 2012-04-30 2012-04-30 Formulação de fármaco de libertação retardada
PT17156227T PT3189830T (pt) 2012-04-30 2013-04-29 Formulação de fármaco de libertação retardada
PT17188821T PT3278792T (pt) 2012-04-30 2013-04-29 Formulação de farmaco de libertação retardada
PT137230330T PT2844222T (pt) 2012-04-30 2013-04-29 Formulação de fármaco de libertação retardada
PT13719543T PT2844220T (pt) 2012-04-30 2013-04-29 Formulação de fármaco de libertação retardada

Family Applications After (4)

Application Number Title Priority Date Filing Date
PT17156227T PT3189830T (pt) 2012-04-30 2013-04-29 Formulação de fármaco de libertação retardada
PT17188821T PT3278792T (pt) 2012-04-30 2013-04-29 Formulação de farmaco de libertação retardada
PT137230330T PT2844222T (pt) 2012-04-30 2013-04-29 Formulação de fármaco de libertação retardada
PT13719543T PT2844220T (pt) 2012-04-30 2013-04-29 Formulação de fármaco de libertação retardada

Country Status (41)

Country Link
US (6) US10226430B2 (enExample)
EP (6) EP2659881B1 (enExample)
JP (2) JP6621662B2 (enExample)
KR (6) KR20190127986A (enExample)
CN (5) CN104302274A (enExample)
AR (1) AR090898A1 (enExample)
AU (4) AU2013255913B2 (enExample)
BR (3) BR112014026935A2 (enExample)
CA (4) CA2871016C (enExample)
CL (2) CL2014002796A1 (enExample)
CO (2) CO7151506A2 (enExample)
CR (4) CR20190246A (enExample)
CU (1) CU24304B1 (enExample)
CY (4) CY1120215T1 (enExample)
DK (5) DK2659881T3 (enExample)
EA (2) EA032811B1 (enExample)
ES (6) ES2987408T3 (enExample)
GE (4) GEP201706736B (enExample)
HR (2) HRP20180068T1 (enExample)
HU (5) HUE036187T2 (enExample)
JO (6) JOP20200144A1 (enExample)
LT (5) LT2659881T (enExample)
ME (2) ME03364B (enExample)
MX (4) MX373249B (enExample)
MY (3) MY190392A (enExample)
NO (1) NO2659881T3 (enExample)
NZ (3) NZ629260A (enExample)
PE (3) PE20142442A1 (enExample)
PH (2) PH12014502339A1 (enExample)
PL (5) PL2659881T3 (enExample)
PT (5) PT2659881T (enExample)
RS (5) RS56839B1 (enExample)
SA (2) SA113340508B1 (enExample)
SG (2) SG11201406798WA (enExample)
SI (5) SI2659881T1 (enExample)
SM (5) SMT201800095T1 (enExample)
TN (2) TN2014000442A1 (enExample)
TR (3) TR201905226T4 (enExample)
TW (3) TWI618547B (enExample)
UY (1) UY34772A (enExample)
WO (2) WO2013164315A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24342B1 (es) * 2012-04-30 2018-05-08 Tillotts Pharma Ag Formulación de fármaco de liberación retardada
NO2659881T3 (enExample) 2012-04-30 2018-04-28
US20140141075A1 (en) * 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
PT2959892T (pt) * 2013-02-22 2020-12-15 Zeria Pharm Co Ltd Comprimido com revestimento entérico
US10799515B2 (en) 2013-10-29 2020-10-13 Tillotts Pharma Ag Delayed release drug formulation
UA117768C2 (uk) 2013-12-24 2018-09-25 Сентісс Фарма Прайвет Лімітед Офтальмологічний розчин тартрату бримонідину для місцевого застосування
EP3915552A1 (en) 2015-06-01 2021-12-01 Xeno Biosciences Inc. Compositions for use in modulating the gut microbiota and managing weight
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
CN105816883B (zh) * 2016-02-03 2018-12-14 华南师范大学 一种负载抗癌药物姜黄素的益生菌叶酸靶向载体及其制备方法
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
WO2018102469A1 (en) * 2016-11-30 2018-06-07 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
WO2019183208A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
EP3768245A4 (en) * 2018-03-23 2023-10-18 Palatin Technologies, Inc. MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDE FORMULATIONS AND METHODS FOR GASTROINTESTINAL TRACT-SPECIFIC ADMINISTRATION
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
ES2994844T3 (en) * 2018-12-07 2025-02-03 Tillotts Pharma Ag Colonic drug delivery formulation
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662900A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
EP3662901B1 (en) * 2018-12-07 2025-01-01 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
DK3666262T3 (da) * 2018-12-10 2022-01-31 Aphaia Ip Ag Farmaceutiske orale doseringsformer til behandling af stofskifteforstyrrelser og lignende sygdomme ved orkestreret frigivelse af enterokiner
CN111617047B (zh) * 2019-02-27 2021-06-22 广州喜鹊医药有限公司 一种含tbn或其盐或其水合物的药物组合物及其制备方法
GB201905940D0 (en) * 2019-04-29 2019-06-12 Intract Pharma Ltd 5-aminolevulinic acid for the local treatment of inflammatory bowel disease
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
CN114340615A (zh) * 2019-08-12 2022-04-12 麻省理工学院 用于施用治疗剂的制品和方法
US20230301927A1 (en) * 2019-11-13 2023-09-28 Ethypharm Process for producing an orally administered pharmaceutical composition with colonic delivery
FR3102931B1 (fr) * 2019-11-13 2021-12-24 Ethypharm Sa Procédé de fabrication d’une composition pharmaceutique à administration orale et à délivrance colonique
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN111567678A (zh) * 2020-05-11 2020-08-25 四川英格瑞生物科技有限公司 无抗畜类肠道保健剂及其制备方法
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
CN116193994A (zh) * 2020-07-13 2023-05-30 麒麟控股株式会社 薄膜包衣片剂
US20240293429A1 (en) * 2021-06-01 2024-09-05 Nbi Biosciences Pvt Ltd Microbial-triggered oral intestinal drug delivery formulation and method of preparation thereof
CN117024341A (zh) * 2022-04-30 2023-11-10 宁波大学 一类d-2a不对称型热活化延迟荧光材料的合成及其应用
CN116898823A (zh) * 2023-08-02 2023-10-20 中国农业大学 一种微囊结构及其制备方法和应用
TW202535387A (zh) * 2023-10-16 2025-09-16 法商拜爾普羅傑特醫藥有限公司 必托里賽（ｐｉｔｏｌｉｓａｎｔ）之新穎調配物及使用方法
CN118806729B (zh) * 2024-06-18 2025-04-22 海南合瑞制药股份有限公司 美沙拉秦肠溶缓释微丸及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5291419A (en) * 1976-01-28 1977-08-01 Fuji Yakuhin Kogyo Kk Coloring image forming photosensitive sheet
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
DE4217920C2 (de) * 1992-05-30 1996-05-09 Goldwell Gmbh Verfahren zur Herstellung von pulverförmigen Mitteln zum Blondieren von menschlichen Haaren
KR0157280B1 (ko) * 1992-11-06 1998-11-16 나까토미 히로타카 하부소화관 방출성의 경구의약제제
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
FR2711525B1 (fr) 1993-10-29 1996-01-12 Virbac Laboratoires Forme Galénique à administration orale pour animaux, son procédé de préparation et ses applications.
US5508276A (en) 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
CN1239425A (zh) * 1996-11-15 1999-12-22 普罗克特和甘保尔公司 供结肠释放的具有多层肠溶聚合物包衣的药剂
CA2236605A1 (en) * 1997-05-09 1998-11-09 Yves Duccini Scale inhibitors
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
ATE238797T1 (de) * 1999-12-16 2003-05-15 Medinfar Produtos Farmaceutico Piroxicam enthaltende gastrointestinale zubereitung aus merheren einheiten bestehend
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
FI20000780L (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
US6939920B2 (en) 2001-01-08 2005-09-06 The Goodyear Tire & Rubber Company Tire sidewall compounds having improved flex fatigue and tread compound having improved tear strength
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
KR20030097892A (ko) 2001-05-25 2003-12-31 에스에스 세야쿠 가부시키 가이샤 의약 배합제
US7183321B2 (en) 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
AU2003304203A1 (en) * 2002-10-29 2005-01-04 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
WO2004058228A1 (en) 2002-12-24 2004-07-15 Lupin Limited Enteric coated fluoxetine composition
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
WO2005092297A2 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1904039A2 (en) 2005-06-20 2008-04-02 Cadila Healthcare Ltd. Controlled release dosage formulation of duloxetine
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP4984695B2 (ja) 2006-07-11 2012-07-25 株式会社明電舎 色素増感型太陽電池及びその製造方法
SK287622B6 (sk) * 2006-07-25 2011-04-05 Peter Pap Odkladacia schránka
WO2008020286A2 (en) 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
WO2008044236A2 (en) * 2006-10-10 2008-04-17 Dexcel Pharma Technologies Ltd. Improved release of statins in the intestine
EP2097067A2 (en) * 2006-12-05 2009-09-09 University Of The Witwatersrand, Johannesburg A heterogeneously configured multiparticulate gastrointestinal drug delivery system
TW200843802A (en) * 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
JP2008214249A (ja) 2007-03-02 2008-09-18 Takeda Chem Ind Ltd 製剤における溶出改善方法および溶出性の改善された製剤
KR20090122489A (ko) * 2007-03-26 2009-11-30 데이코쿠 세이야쿠 가부시키가이샤 결장-특이적 전달을 위한 경구적 약제학적 제제
AU2007352872B2 (en) * 2007-05-07 2013-03-14 Evonik Operations Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
US20090162434A1 (en) 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
EP2486918A4 (en) * 2009-10-09 2014-02-26 Yungjin Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION WITH BOTH IMMEDIATE AND DELAYED RELEASE
EP2384746A3 (en) 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
WO2012075015A2 (en) 2010-11-29 2012-06-07 Dr. Reddy's Laboratories Ltd. Oral metronidazole pharmaceutical compositions
EP2753310B1 (de) 2011-09-07 2021-03-24 Roland Saur-Brosch Formulierung zur kontrollierten freisetzung eines oder mehreren stoffe im verdauungstrakt eines säugetiers
CN102319218B (zh) 2011-09-22 2014-10-01 贝沃特医药技术(上海)有限公司 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法
NO2659881T3 (enExample) 2012-04-30 2018-04-28
US9844436B2 (en) 2012-10-26 2017-12-19 Edwards Lifesciences Corporation Aortic valve and conduit graft implant tool
US10799515B2 (en) 2013-10-29 2020-10-13 Tillotts Pharma Ag Delayed release drug formulation

Also Published As

Publication number Publication date
SA115370043B1 (ar) 2016-05-24
KR20150004910A (ko) 2015-01-13
NZ629260A (en) 2017-01-27
MX373249B (es) 2020-05-12
ME03641B (me) 2020-07-20
HUE043238T2 (hu) 2019-08-28
JOP20200147A1 (ar) 2022-10-30
AU2013255914B2 (en) 2017-08-31
BR112014026933A2 (pt) 2017-06-27
SI2844222T1 (sl) 2020-02-28
AU2013255914A1 (en) 2014-11-13
LT3278792T (lt) 2019-05-10
US9814681B2 (en) 2017-11-14
US11534406B2 (en) 2022-12-27
PT3189830T (pt) 2018-10-19
DK2659881T3 (en) 2018-02-05
JO3574B1 (ar) 2020-07-05
MY190392A (en) 2022-04-20
JOP20200148B1 (ar) 2023-09-17
CY1121609T1 (el) 2020-05-29
JP6621661B2 (ja) 2019-12-18
ES2673931T3 (es) 2018-06-26
PH12014502339B1 (en) 2014-12-22
US9364440B2 (en) 2016-06-14
MX366677B (es) 2019-07-19
MY169161A (en) 2019-02-19
EP3278792A1 (en) 2018-02-07
HUE037702T2 (hu) 2018-09-28
EP2659881A1 (en) 2013-11-06
TWI700102B (zh) 2020-08-01
DK3189830T3 (en) 2018-07-16
TWI705833B (zh) 2020-10-01
RS58625B1 (sr) 2019-05-31
KR20150004911A (ko) 2015-01-13
BR122019022551B1 (pt) 2022-07-19
KR102198621B1 (ko) 2021-01-06
PL2844220T3 (pl) 2019-06-28
CA2871017A1 (en) 2013-11-07
CN110200949B (zh) 2021-11-16
CN110237056A (zh) 2019-09-17
EP3187171C0 (en) 2024-09-25
AU2017210571B2 (en) 2018-11-29
PT2844220T (pt) 2019-03-27
RS57431B1 (sr) 2018-09-28
EA201491783A1 (ru) 2014-12-30
HRP20180965T1 (hr) 2018-08-10
KR102102198B1 (ko) 2020-04-21
GEP201706753B (en) 2017-10-25
KR20190127984A (ko) 2019-11-13
JOP20200148A1 (ar) 2022-10-30
LT2844220T (lt) 2019-04-10
WO2013164315A1 (en) 2013-11-07
EP3187171A1 (en) 2017-07-05
CU24304B1 (es) 2018-01-10
ME03364B (me) 2019-10-20
MX362529B (es) 2019-01-23
ES2761341T3 (es) 2020-05-19
ES2720258T3 (es) 2019-07-19
RS58735B1 (sr) 2019-06-28
PL2844222T3 (pl) 2020-03-31
ES2987408T3 (es) 2024-11-14
JP2015515964A (ja) 2015-06-04
JOP20200145B1 (ar) 2023-09-17
US20150125525A1 (en) 2015-05-07
CO7151506A2 (es) 2014-12-29
JOP20200147B1 (ar) 2023-09-17
GEP201706758B (en) 2017-10-25
SG11201406798WA (en) 2014-11-27
AU2017210571A1 (en) 2017-08-24
EP3189830B1 (en) 2018-05-23
PH12014502339A1 (en) 2014-12-22
JP2015515965A (ja) 2015-06-04
JOP20200146B1 (ar) 2023-09-17
TW201343202A (zh) 2013-11-01
CU20140123A7 (es) 2015-02-26
CN110200949A (zh) 2019-09-06
EP3189830A1 (en) 2017-07-12
WO2013164316A1 (en) 2013-11-07
US20140056980A1 (en) 2014-02-27
HUE036187T2 (hu) 2018-06-28
US20150132380A1 (en) 2015-05-14
SA113340508B1 (ar) 2016-02-07
SI2659881T1 (en) 2018-03-30
US10272048B2 (en) 2019-04-30
MX2014012887A (es) 2015-05-08
SMT201900215T1 (it) 2019-05-10
US20170266117A1 (en) 2017-09-21
JP6621662B2 (ja) 2019-12-18
PL3278792T3 (pl) 2019-09-30
PE20150129A1 (es) 2015-02-13
BR112014026933B1 (pt) 2022-07-19
CA2871016A1 (en) 2013-11-07
AU2013255913B2 (en) 2017-08-31
AR090898A1 (es) 2014-12-17
CL2014002795A1 (es) 2015-02-13
EA201491781A1 (ru) 2014-12-30
SMT202000014T1 (it) 2020-03-13
CA3052460C (en) 2022-06-07
EA032514B1 (ru) 2019-06-28
EP2844222B1 (en) 2019-11-13
EP2844222A1 (en) 2015-03-11
CL2014002796A1 (es) 2015-02-06
PH12014502340A1 (en) 2014-12-22
US10226430B2 (en) 2019-03-12
PE20142442A1 (es) 2015-01-28
SG11201406799XA (en) 2014-11-27
TR201809416T4 (tr) 2018-07-23
CN110237056B (zh) 2022-03-08
SMT201800360T1 (it) 2018-09-13
SMT201900252T1 (it) 2019-07-11
DK3278792T3 (da) 2019-05-06
TW201720430A (zh) 2017-06-16
AU2017210577A1 (en) 2017-08-24
NZ725409A (en) 2018-05-25
UY34772A (es) 2013-11-29
NZ629262A (en) 2017-01-27
US11517534B2 (en) 2022-12-06
EP2659881B1 (en) 2017-11-29
HRP20180068T1 (hr) 2018-03-23
BR112014026935A2 (pt) 2017-06-27
LT2659881T (lt) 2018-02-12
MX2014012888A (es) 2015-04-13
MY169088A (en) 2019-02-15
GEP201706736B (en) 2017-09-25
PT2844222T (pt) 2019-12-30
CR20140486A (es) 2015-01-19
AU2017210577B2 (en) 2018-11-29
CY1120215T1 (el) 2018-12-12
RS56839B1 (sr) 2018-04-30
CA3052460A1 (en) 2013-11-07
PE20190625A1 (es) 2019-04-26
CN104271113B (zh) 2019-03-22
MX367127B (es) 2019-08-06
EP3187171B1 (en) 2024-09-25
CN104302274A (zh) 2015-01-21
SMT201800095T1 (it) 2018-03-08
CR20190245A (es) 2019-07-29
TR201903569T4 (tr) 2019-04-22
DK2844222T3 (da) 2019-12-09
KR102104070B1 (ko) 2020-04-24
HUE042833T2 (hu) 2019-07-29
ES2714448T3 (es) 2019-05-28
TWI618547B (zh) 2018-03-21
RS59697B1 (sr) 2020-01-31
JOP20200145A1 (ar) 2022-10-30
EP3278792B1 (en) 2019-02-20
PH12014502340B1 (en) 2014-12-22
AU2013255913A1 (en) 2014-11-13
CN106983735A (zh) 2017-07-28
GEP201706759B (en) 2017-10-25
SI2844220T1 (sl) 2019-05-31
HUE046628T2 (hu) 2020-03-30
DK2844220T3 (en) 2019-04-08
CY1122475T1 (el) 2021-01-27
CN104271113A (zh) 2015-01-07
TW202037370A (zh) 2020-10-16
US20170035698A1 (en) 2017-02-09
TN2014000442A1 (en) 2016-03-30
EP2844220B1 (en) 2019-01-23
JOP20200144A1 (ar) 2017-06-16
KR20200075024A (ko) 2020-06-25
LT3189830T (lt) 2018-07-10
NO2659881T3 (enExample) 2018-04-28
PL3189830T3 (pl) 2018-11-30
KR20190127986A (ko) 2019-11-13
CA2871016C (en) 2023-03-21
SI3278792T1 (sl) 2019-06-28
EP2844220A1 (en) 2015-03-11
KR20200073296A (ko) 2020-06-23
TN2014000441A1 (en) 2016-03-30
JOP20200146A1 (ar) 2022-10-30
KR102177773B1 (ko) 2020-11-12
EA032811B1 (ru) 2019-07-31
LT2844222T (lt) 2019-12-27
US20200214987A1 (en) 2020-07-09
CY1120492T1 (el) 2019-07-10
CR20140485A (es) 2015-01-19
PT3278792T (pt) 2019-05-23
PL2659881T3 (pl) 2018-05-30
CO7141433A2 (es) 2014-12-12
ES2655622T3 (es) 2018-02-20
SI3189830T1 (en) 2018-08-31
CR20190246A (es) 2019-09-03
CA3080035A1 (en) 2013-11-07
TR201905226T4 (tr) 2019-05-21

Similar Documents

Publication Publication Date Title
US11534406B2 (en) Delayed release drug formulation
US10799515B2 (en) Delayed release drug formulation
BRPI0710195B1 (pt) Formulação de medicamento de liberação retardada para dispensação de um medicamento ao cólon, uso de uma formulação, e, métodos para preparar uma formulação de medicamento de liberação retardada
HK1202266A1 (en) A delayed release drug formulation
HK1202266B (en) A delayed release drug formulation
HK1202267B (en) A delayed release drug formulation